Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Controlled Phase 2 Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Traumatic Brain Injury (TBI)

NCT02416492 is registered in ClinicalTrials.gov with SanBio, Inc. as lead sponsor.

NCT NCT02416492
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02416492 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Controlled Phase 2 Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Traumatic Brain Injury (TBI)
Lead sponsor
SanBio, Inc.
Phase
Phase 2
Overall status
Completed
Start date
July 6, 2016
Completion date
March 5, 2019
Enrollment
63 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

traumatic brain injury